<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02379468</url>
  </required_header>
  <id_info>
    <org_study_id>EEPI_ PED_001</org_study_id>
    <nct_id>NCT02379468</nct_id>
  </id_info>
  <brief_title>Efficacy &amp; Safety of Pedyphar Ointment in Diabetic Foot Ulcer Treatment</brief_title>
  <acronym>PEDFUT</acronym>
  <official_title>Phase IIIb, A Prospective, Open Label, Randomized, Controlled, Parallel Group, Multicenter Clinical Trial of 3 Months Duration Comparing Topical Application of Royal Jelly and Panthenol (PEDYPHAR® Ointment) to Panthenol Ointment Only for Diabetic Foot Ulcers Treatment.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Egyptian Pharmaceutical Industries</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>European Egyptian Pharmaceutical Industries</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of Pedyphar® ointment in the
      healing of foot ulceration in diabetic patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">August 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of diabetic patients with successful healing of foot ulceration in treated with Pedyphar® ointment</measure>
    <time_frame>12 weeks</time_frame>
    <description>Efficacy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to complete wound healing within 12 weeks before the end of treatment duration.</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the healing process of Diabetic foot ulcer using Pedyphar® ointment compared with Panthenol ointment regarding changes of foot ulcer dimensions from baseline visit to the end of the study.</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To identify the reasons of treatment failure and delayed response</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To identify adverse events associated with the application of Pedyphar® ointment.</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Diabetic Foot Ulcer</condition>
  <arm_group>
    <arm_group_label>Pedyphar</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ointment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panthenol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ointment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pedyphar Ointment</intervention_name>
    <arm_group_label>Pedyphar</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Panthenol</intervention_name>
    <description>Ointment</description>
    <arm_group_label>Panthenol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Written informed consent signed and dated by study subject.

          2. Male or Female patients.

          3. Age is ≥18 years old and ≤ 70 years old.

          4. Clinical diagnosis of Diabetes Mellitus Type I or II with diabetic foot ulcer. A past
             history of Diabetes Mellitus and/or the use of anti-diabetic medications for the
             treatment of Diabetes Mellitus with diabetic foot ulcer are sufficient.

          5. Presence of 1 or more DFU, less than 15 cm in its biggest diameter, with a Texas
             University grade ≤ 2 and ≤ grade 2 according to the Wagner Grading system.

          6. Diabetic foot ulcer has been present for at least 4 weeks and no more than 2 years
             prior to screening.

          7. If there is Diabetic Foot Ulcer Infection, It must be:

               1. Mild ( Presence of ≥ 2 manifestations of inflammation (purulence, or erythema,
                  pain, tenderness, warmth, or indurations),any cellulitis/erythema extending ≤ 2
                  cm around the ulcer, and infection is limited to the skin or superficial
                  subcutaneous tissues; no other local complications or systemic illness).

                  Or:

               2. Moderate Infection (as above) in a patient who is systemically well and
                  metabolically stable but which has ≥1 of the following characteristics:
                  cellulitis extending &gt;2 cm, lymphangitic streaking, spread beneath the
                  superficial fascia, deep-tissue abscess, gangrene, and involvement of muscle,
                  tendon, joint or bone.

          8. If subject is female and of childbearing potential, she agrees to use a medically
             acceptable physical barrier method contraceptive during the treatment phase.

          9. Be willing and able to participate in the study as an outpatient, make the required
             visits to the study center during the treatment periods, and comply with study
             requirements.

         10. Receiving medical care for diabetes.

        Exclusion Criteria:

          1. DFU with a Texas score &gt;2 and &gt; grade 2 according to the Wagner Grading system.

          2. Severe Infected DFU with clinical or para-clinical findings suggesting osteomyelitis
             (Infection in a patient with systemic toxicity or metabolic instability (e.g., fever,
             chills, tachycardia, hypotension, confusion, vomiting, leukocytosis, acidosis, severe
             hyperglycemia, or azotemia)

          3. Clinically defined and documented severe arterial disease.

          4. History of radiation therapy to the ulcer site.

          5. If the study subject has Foot Ulcer of no diabetic pathophysiology.

          6. Receiving corticosteroids or immune suppressive agents.

          7. History of immune-vascular disease.

          8. Known hypersensitivity to any component of Pedyphar® or Panthenol.

          9. Patients undergoing hemodialysis.

         10. Insufficient blood supply to Lower Limb (ankle-brachial index &lt; 0.9).

         11. Clinical findings suggesting complicated venous insufficiency of LL. Edema [Hyper
             pigmentation, Venous dermatitis, Chronic cellulitis, Cutaneous infarction (atrophie
             blanche), Ulceration]

         12. Received treatment with any other investigational drug or device within the last 30
             days

         13. Unable to comply with the procedures described in the protocol

         14. History of moderate to severe ischemic heart disease or any history of congestive
             heart failure, or has had a myocardial infarction within the previous 6 months.

         15. Patients with a history of major hematological, renal or hepatic abnormalities.

         16. Mentally or neurologically disabled patients that are considered not fit to approve
             their participation in the study.

         17. Refusal to give informed consent.

         18. Pregnant or Breastfeeding subjects.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Samir H. Asaad, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Alexandria University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tanta University</name>
      <address>
        <city>Tanta</city>
        <state>Please select</state>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alexandria University</name>
      <address>
        <city>Alexandria</city>
        <zip>21500</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ain Shames University</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Suez Canal University</name>
      <address>
        <city>Suez</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 19, 2015</study_first_submitted>
  <study_first_submitted_qc>March 4, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 5, 2015</study_first_posted>
  <last_update_submitted>March 4, 2015</last_update_submitted>
  <last_update_submitted_qc>March 4, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 5, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetic</keyword>
  <keyword>Foot</keyword>
  <keyword>Ulcer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Diabetic Foot</mesh_term>
    <mesh_term>Foot Ulcer</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pantothenic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

